ACHV vs HELP: fair value comparison
Achieve Life Sciences, Inc. and Cybin D/B/A Helus Pharma · Updated 2026-10-19
ACHV has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. HELP has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ACHV currently ranks higher by quality score.
| ACHV | HELP | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $6.38 | $10.55 |
| 12-month range | $2.65–$8.53 | $3.87–$14.02 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #291 of 301 Healthcare | #293 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | — |
| Margin trend | Contracting | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ACHV fair value analysis · HELP fair value analysis